Pulmonary Disease Doctors in Manahawkin, NJ Accepting Medicare

3 Pulmonary Disease doctors found. Showing 1 - 3

Jeffrey M. Lipper, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1364 Route 72 W, Manahawkin, NJ 08050 Phone: 609-597-3416    Fax: 609-597-9608

Frederic Dewil, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1301 Route 72 W Ste 300, Manahawkin, NJ 08050 Phone: 609-597-6513    Fax: 609-597-4593

Raymond P Mantovani, MD Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1301 Route 72 W, Suite 300, Manahawkin, NJ 08050 Phone: 609-597-6513    Fax: 609-597-4593

News Archive

Springer publishes Principles of Research Methodology: A Guide for Clinical Investigators

How do you teach medical research? How do you design a good study or develop a workable hypothesis? How do you shape research to improve patient care? These and many more questions are addressed in an authoritative textbook detailing the clinical research process, written by researchers and clinicians at SUNY Downstate Medical Center and other institutions.

Cannabinoid receptors regulate memory processes by modulating mitochondrial energy metabolism

It has been known for some time that the extracts of the Cannabis plant, just like synthetic cannabinoids and those produced by the brain itself, join up with type 1 (CB1) cannabinoid receptors located in the nerve endings of the neurons, and inhibit the release of chemical messengers (neurotransmitters) in the communication areas between the nerve cells.

PIONEER trial evaluates new safe concept of stent-drug combination

Blue Medical today announced a major step forward in its quest to improve the quality of life of patients with cardiovascular disease, with the start of the PIONEER trial, in which a new safe concept of stent-drug combination is evaluated.

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis.

Perampanel drug can effectively treat seizures in patients with epilepsy

A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug.

Read more Medical News

› Verified 4 days ago